NUTLEY, N.J., April 12, 2024 /PRNewswire/ -- Eisai Inc. announced today the Company will present findings from its robust neurology portfolio, including data from the Phase 3 Clarity AD trial for LEQEMBI® (lecanemab-irmb), Eisai's anti-amyloid beta (A?) protofibril* antibody for the treatment of early Alzheimer's disease (AD), as well as data on its insomnia dual orexin receptor antagonist DAYVIGO® (lemborexant) CIV at the American Academy of Neurology® (AAN) Annual Meeting. The meeting will be held in Denver, Colorado, and virtually from April 13-18, 2024.
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today new presentations featuring the latest data about the company's insomnia medication DAYVIGO (lemborexant) will be presented at the 35th annual SLEEP 2021 meeting of the Associated Professional Sleep Societies, LLC (APSS). SLEEP is a joint venture of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS) and which will be held virtually from June 10 to June 13, 2021.
Eisai Co, Ltd announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist Dayvigo (lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. This approval is the first approval for Dayvigo in Asia outside of Japan.
MISSISSAUGA, ON, Feb. 4, 2021 /CNW/ - Eisai Limited, the Canadian subsidiary of Eisai Inc., today announced the Canadian authorization and availability of a new non-sedative prescription medication, DAYVIGO™ (lemborexant). Available in both 5 mg and 10 mg dosages, DAYVIGO is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and / or sleep maintenance.1
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced findings from several post hoc analyses of DAYVIGO™ from the Phase 3 SUNRISE 1 and 2 clinical studies and top-line results from an open label pilot study.
WOODCLIFF LAKE, N.J., Aug. 24, 2020 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will present new DAYVIGO™ (lemborexant) CIV research at the SLEEP 2020 virtual conference, the 34th annual meeting of the Associated Professional Sleep Societies, August 27-30, 2020. DAYVIGO, a dual orexin receptor antagonist, was recently launched in the U.S. for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.1
WOODCLIFF LAKE, N.J., Aug. 24, 2020 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will present new DAYVIGO™ (lemborexant) CIV research at the SLEEP 2020 virtual conference, the 34th annual meeting of the Associated Professional Sleep Societies, August 27-30, 2020. DAYVIGO, a dual orexin receptor antagonist, was recently launched in the U.S. for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.1
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and information from the company's robust AD pipeline, including BAN2401 and lemborexant. This data will be among nine abstracts communicated in one oral and eight poster presentations at the virtual Alzheimer's Association International Conference (AAIC), July 27-31, 2020.
Eisai Co., Ltd. announced that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist Dayvigo (lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, has been accepted by the Hong Kong Department of Health. This application is the first application for Dayvigo in Asia outside of Japan. Eisai plans to continue further applications for approval in respective Asian countries.
TOKYO, Jul 8, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, has been accepted by the Hong Kong Department of Health. This application is the first application for DAYVIGO in Asia outside of Japan. Eisai plans to continue further applications for approval in respective Asian countries.